Selank: the anxiolytic peptide — mechanism, dosing, and clinical evidence

Selank (TP-7) is a synthetic analogue of tuftsin, a natural tetrapeptide derived from IgG immunoglobulin that plays a role in immune regulation and cognitive function. Developed by the Russian Institute of Molecular Genetics (Moscow), Selank's sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was approved as an anxiolytic drug in Russia in 2009 under the brand name Selank. In the United States it is available as a prescription compounded peptide through 503A pharmacies, requiring a valid physician prescription.

Selank's anxiolytic effects operate through multiple mechanisms. GABA receptor modulation: Selank upregulates GABAergic transmission without directly binding benzodiazepine receptor sites — producing anxiolytic effects without sedation, tolerance development, or withdrawal syndrome. BDNF upregulation: Selank increases brain-derived neurotrophic factor expression, relevant to memory, neuroplasticity, and mood regulation. IL-6 modulation: reduces pro-inflammatory cytokine signaling in the CNS, contributing to its anxiolytic profile. Enkephalinase inhibition: Selank inhibits the enzyme that breaks down met-enkephalin, extending its anxiolytic and cognitive effects.

Phase III clinical trial (n=62): Selank at 0.9mg/day intranasal was compared to diazepam at 5mg/day oral. The Hamilton Anxiety Scale showed equivalent reduction at 4 weeks. The Selank group reported no sedation, no cognitive impairment, and no withdrawal symptoms upon discontinuation. The diazepam group showed significant sedation and cognitive impairment. This is the primary comparative trial; it was conducted in Russia and has not been independently replicated in Western clinical trials, which is the primary limitation of the evidence base.

Selank's enkephalinase inhibition extends the half-life of met-enkephalin, which has downstream effects on memory consolidation and learning speed. Animal studies consistently show improved maze learning performance. A human pilot study (n=18) showed improved recall at 24 hours for a word-learning task performed 30 minutes after 500mcg intranasal Selank vs placebo. The cognitive effects are modest compared to Semax but consistent — they are most relevant in high-cognitive-load contexts where anxiety is also present.

Intranasal route is preferred for convenience and onset speed. Dose: 250–500mcg per administration, delivered as 2–3 drops per nostril (approximately 100–150mcg per drop). Timing: twice daily — morning and mid-afternoon. Evening administration should be avoided due to a mild energizing effect that can interfere with sleep onset. Injectable route: 250–500mcg subcutaneous with identical timing. Cycle length: 4–8 weeks followed by a 2-week break. No tolerance development has been documented at therapeutic doses in clinical data.

Selank is most appropriate for: generalised anxiety of mild to moderate severity, situational high-stress periods (exams, high-stakes professional phases), cognitive load optimization where anxiety is a limiting factor, situational or post-trauma anxiety used as an adjunct to primary treatment, and patients who have intolerable side effects from SSRIs but need anxiolytic support. It is not appropriate as a standalone treatment for clinical anxiety disorders, major depression, PTSD, or panic disorder.

Selank has no documented addiction potential — it does not produce dependence or withdrawal because it does not directly bind benzodiazepine receptor sites. No sedation at therapeutic doses. No cognitive impairment — notably the opposite, mild cognitive enhancement. Mild nasal discomfort with intranasal route is the most commonly reported side effect, and it is transient. Comparing to standards: benzodiazepines cause dependence, sedation, and memory impairment with chronic use. SSRIs have 2–6 week onset and commonly cause sexual dysfunction. Selank offers rapid onset, no dependence, and no cognitive impairment — a meaningfully different risk profile.

Semax is another Russian peptide with primary nootropic effects and secondary anxiolytic activity. It has stronger cognitive enhancement potency but is a less pure anxiolytic than Selank. Common combination: Selank in the morning for anxiolytic baseline, Semax pre-cognitive task for nootropic augmentation. For GLP-1 patients experiencing anxiety about body changes, appetite loss, and protocol adherence: Selank combined with BPC-157 (gut protection) addresses both the GI and psychological dimensions of GLP-1 therapy simultaneously. A physician should design any multi-peptide protocol.

Physician consultation, protocol design, and PCAB-accredited pharmacy access. Prescriptions issued for individual patients only.

Frequently Asked Questions